CN105902696A - Application of Viola yedoensis in preparation of drug for preventing and treating infection of dengue II viruses - Google Patents
Application of Viola yedoensis in preparation of drug for preventing and treating infection of dengue II viruses Download PDFInfo
- Publication number
- CN105902696A CN105902696A CN201610508598.4A CN201610508598A CN105902696A CN 105902696 A CN105902696 A CN 105902696A CN 201610508598 A CN201610508598 A CN 201610508598A CN 105902696 A CN105902696 A CN 105902696A
- Authority
- CN
- China
- Prior art keywords
- application
- dengue
- herba violae
- viruses
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to application of Viola yedoensis in preparation of a drug for preventing and treating infection of dengue II viruses. According to the application, a Viola yedoensis aqueous extract is capable of obviously inhibiting the dengue II viruses and can be used for treating the drug for preventing and treating the infection of the dengue II viruses. The drug for preventing and treating the infection of the dengue II viruses is a clinically acceptable solid or liquid oral preparation prepared from the Viola yedoensis aqueous extract and a conventional dosage of medically acceptable auxiliary materials.
Description
Technical field
The present invention relates to, containing the pharmaceutical preparation not determining structure from plant, be specifically related to Violaceae Viola Herba Violae plant
New application in pharmacy.
Background technology
Dengue virus belongs to flaviviridae, Flavivirus in classification.Including 4 different serotypes, i.e. I, II, III, IV type
Dengue virus.Dengue fever is the acute infectious disease caused by dengue virus, is mainly propagated by Aedes aegypti and Aedes albopictus, passes
The approach of broadcasting is infected after yellow-fever mosquito bites the blood of viremia patient.The highest heat of clinical manifestation, headache, muscle and joint
Bitterly, erythra, lymphadenectasis and leukopenia etc., severe patient may occur in which hemorrhage or shock, even dead.This disease mainly stream
Row is in subtropical and tropical zones, and existing more than 100 countries and regions, the whole world have case to occur at present, have at about 25～3,000,000,000 people
In the danger of dengue virus infection.This disease has had a strong impact on the healthy of people and socio-economic development.Due at present
There is no dengue vaccine, also lack corresponding antiviral drugs, how tackling this emerging infectious disease has become medicine sector and has needed badly
The key subjects of reply.
Herba Violae (Viola yedoensis) is Violaceae (Violaceae) Viola (Viola L.) herbaceos perennial, has another name called light
Calyx common violet, Herba Violae japonicae, Herba Violae and Herba Violae etc..Taste bitter, acrid, cold.GUIXIN, lung meridian.Having heat-clearing and toxic substances removing, removing heat from blood disappears
Swollen, the effect of clearing away heat-damp and promoting diuresis, cure mainly furuncle, carbuncle, scrofula, jaundice, dysentery, diarrhoea, conjunctival congestion, sore throat, venom.
Modern pharmacology research finds that it has preferable antiviral, antiinflammatory, antibacterial and anti-tumor activity.It is used for clinically treating furuncle
Pyogenic infections from tumour or sore, urinary tract infection, cellulitis, mastitis, pharyngitis, dysentery, jaundice, conjunctival congestion and swelling pain etc..Document report at present
In Herba Violae anti-dengue virus active reporter and the application in terms of anti-dengue virus thereof the most do not occur.
Summary of the invention
The technical problem to be solved is to provide Herba Violae new application in pharmacy.
Specifically, Herba Violae is preparing the application prevented and treated in the medicine that dengue fever II type virus infects to above-mentioned new application.
In above-mentioned application, described medicine is that the medically acceptable adjuvant of Herba Violae water extract and conventional amount used is made
The most acceptable solid or liquid oral medicine.
In above-mentioned application, the most acceptable granule of described solid orally ingestible, capsule or tablet.
In above-mentioned application, the most acceptable oral liquid of described liquid oral medicine.
In above-mentioned application, described Herba Violae water extract can use method extraction commonly used in the art to obtain.The present inventor pushes away
The method recommended is as described below:
Water extract of the present invention is to obtain by the reflux, extract, that water is solvent employing routine, and wherein, what the present inventor recommended carries
Access method is the most as described below.
Take Herba Violae medical material, add 10 times of water, reflux, extract, 30 minutes, let cool, filter, take filtrate, concentrate, dry
Dry, obtain Herba Violae water extract.
The preparation method of solid orally ingestible of the present invention is the customary preparation methods of defined in pharmacopeia, will pale reddish brownly
The conventional adjuvant of fourth water extract and solid orally ingestible is mixed to prepare by can accept proportioning clinically.
The preparation method of liquid oral medicine of the present invention is the customary preparation methods of defined in pharmacopeia, will pale reddish brownly
Adjuvant conventional with liquid oral medicine after fourth water extract dilute mix by can accept proportioning clinically, stirs evenly, filtration,
Fill, sterilizing, to obtain final product.
Solid orally ingestible of the present invention or liquid oral medicine have the effect of anti-II type dengue virus, can be used for preventing
Control dengue infection.
Drug safety and the beneficial effect of the present invention is further illustrated below by way of experiment.
The present invention is the inhibitory action using cytopathic-effect inhibition assay research Herba Violae water extract to dengue fever II type virus, sees
Examine Herba Violae water extract to the toxic action of BHK-21 cell and the inhibitory action to dengue fever II type virus, utilization
CCK-8 detectable records the half poisonous concentration (CC of test medicine50) it is 35.21, half ceiling effect concentration (EC50)
Being 12.92, it selects index SI to be 2.73, efficient for low toxicity.Specific experiment method is as described below.
1. experiment material
1.1 cell strains breast hamster kidney cell (BHK-21), quoted from Wuhan institute of viruses, T11 generation.The frozen conservation in this room.
1.2 experimental grouies and the test medicine of correspondence thereof
Given the test agent: take off state embodiment 1 preparation Herba Violae water extract be dissolved in water, prepare be equivalent to every milliliter contained
The medicinal liquid of 100mg.
1.3 Strain dengue type-2 viruses are quoted from Wuhan institute of viruses
1.3 reagent and instrument newborn calf serum and DMEM culture medium (Gibco company)；DMSO (foreignize by Guangzhou health
Work company limited)；DIFCO company of the trypsin U.S.；Shanghai Sheng Gong bio-engineering corporation is acted on behalf of).Olympus PM-6
Inverted microscope (OLYMPUS company of Japan)；；E-52AA Rotary Evaporators (Shanghai Yarong Biochemical Instrument Plant)；BP221S
Electronic analytical balance (Shanghai precision instrument table company limited).
2. method
2.1 Herba Violae water extracts mensuration of toxic concentration on BHK-21 cell
It is 0.5 × 10 by density5Cell/ml BHK-21 cell is inoculated in 96 porocyte culture plates, every hole 100 μ L.Growth
24h cell (80-90%) in flakes is adherent rear standby.By medicine cell maintenance culture solution (containing 2% serum) from continuous 2 times of ladders
Degree 6 gradients of dilution, every hole adds institute preparating liquid 100 μ L, if normal cell controls, every hole adds 100 μ L cell dimensions
Hold culture fluid.If solvent control group, in the 5%CO of 37 DEG C2Incubator is cultivated.Dosing adds containing 100 μ L after cultivating 48h
The culture medium of 10%CCK-8 reagent, hatches 1h at 37 DEG C.Calculate according to following method:
Detecting absorbance with 450nm, the toxicity of cell is represented by medicine with the activity of cell, computing formula:
Cell viability (%)=(medicine group-blank)/(cell controls-blank) × 100%.
The mensuration of 2.2 viral suppression
Growth selection is vigorous, the good cell of stratification, tipping growth-promoting media, adds trypsinization, makes cell suspension with growth-promoting media dispersion
Concentration is 105Individual/hole.With pipettor, cell suspension is added in 96 orifice plates, every hole 100uL.Culture plate is placed in incubator
Middle cultivation 12～18 hours, after cell grows up to monolayer in 96 orifice plates, suck culture fluid, and every hole adds 100ul not
Medicine and the 100TCID of 100uL with diluted concentration50Virus liquid, each drug level arranges 2 multiple holes, arranges sky simultaneously
White matched group, normal cell controls group, virus control group and positive controls, be placed in incubator and hatch 1h, sucks pastille training
Nutrient solution and virus liquid.Suck maintenance liquid when virus control group 75%-100% pathological changes, add 100 μ L 10%CCK-8, at enzyme
Mark instrument 450nm measures absorbance, calculates the viral suppression of medicine.
Viral suppression=(test group mean OD value-virus control group mean OD value)/(cell controls group mean OD value-virus
Matched group mean OD value) × 100%
3. result
3.1 drug toxicity results such as table 1.
Table 1
The measurement result of 3.2 drug on viral suppression ratio such as table 2.
Table 2
Above-mentioned test result indicate that water extract of the present invention has obvious inhibiting effect to dengue type-2 virus.Index is selected to be more than 2,
Can be used for preparing the treatment and prevention medicine of dengue fever.
Detailed description of the invention
Example 1:
Take dry Herba Violae herb 10kg, add 100L distilled water immersion 30 minutes, decoct 30 minutes, filtered while hot,
It is concentrated into the thick extractum of 1.05～1.1 proportions, is dried, obtains Herba Violae water extract.
Example 2:(granule)
The water extract 300g of Example 1, adds the adjuvant such as sucrose, dextrin, is placed in fluid bed granulator and mixes, pelletizes, does
Dry, subpackage, every bag of 9g.This product is brown-green granule, and taste is micro-sweet, bitter.Other project should meet Pharmacopoeia of People's Republic of China
Pertinent regulations under version granule item in 2010.
Example 3:(capsule)
The water extract 300g of Example 1, adds the adjuvant such as starch, is placed in fluid bed granulator and mixes, pelletizes, dry.Will
Gained granule loads in No. 1 hard gelatin capsule, every 0.3g, subpackage 100.This product is capsule, and content is brown-green
Granule or powder, mildly bitter flavor, for orally using.Other project should meet Pharmacopoeia of People's Republic of China version capsule in 2010
Pertinent regulations under agent item.
Example 4:(tablet)
The water extract 100g of Example 1, adds the adjuvant such as starch, is placed in fluid bed granulator and mixes, pelletizes, adds after drying
Enter appropriate magnesium stearate tabletting, every 0.2g, subpackage 500.This product is brown-green tablet, mildly bitter flavor, for orally using.
Other project should meet the pertinent regulations under Pharmacopoeia of People's Republic of China tablet item in 2010.
Example 5:(oral liquid)
The water extract 50g of Example 1, add water appropriate dissolving, filters, and adds simple syrup and sodium benzoate is appropriate, add water to
1000ml, stirs evenly, and stands, and filters, embedding, sterilizing, every 10ml.This product is brown supernatant liquid, taste bitter confession sweet, micro-
Orally use.Other project should meet the pertinent regulations under Pharmacopoeia of People's Republic of China oral liquid item in 2010.
Claims (4)
1. Herba Violae application in the medicine that preparation preventing and treating dengue fever II type virus infects.
Application the most according to claim 1, is characterized in that, described medicine is by Herba Violae water extract and conventional amount used
The most acceptable solid made of medically acceptable adjuvant or liquid oral medicine.
Application the most according to claim 2, is characterized in that, described solid or liquid oral medicine are granule, capsule
Agent, tablet or oral liquid.
4. according to the application described in Claims 2 or 3, it is characterized in that, described Herba Violae water extract is prepared by following methods
Obtain:
Take Herba Violae, add 10 times of water, reflux, extract, 30 minutes, let cool, filter, take filtrate, concentrate, be dried, i.e.
Obtain Herba Violae water extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610508598.4A CN105902696B (en) | 2016-06-29 | 2016-06-29 | Application of the viola mandshurica in the drug of preparation prevention and treatment II type virus infection of dengue fever |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610508598.4A CN105902696B (en) | 2016-06-29 | 2016-06-29 | Application of the viola mandshurica in the drug of preparation prevention and treatment II type virus infection of dengue fever |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105902696A true CN105902696A (en) | 2016-08-31 |
| CN105902696B CN105902696B (en) | 2019-07-05 |
Family
ID=56753783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610508598.4A Active CN105902696B (en) | 2016-06-29 | 2016-06-29 | Application of the viola mandshurica in the drug of preparation prevention and treatment II type virus infection of dengue fever |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105902696B (en) |
-
2016
- 2016-06-29 CN CN201610508598.4A patent/CN105902696B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105902696B (en) | 2019-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101711796B (en) | Application of scullcapflavone in preparing medicament for treating enterovirus infection | |
| CN102824417B (en) | New method for treating helicobacter pylori related diseases | |
| CN1813711B (en) | Use of isoflavone compound | |
| CN102240286B (en) | Application of matrine to medicament for treating or preventing enterovirus 71 type infection | |
| CN108524685A (en) | A kind of composition that treating children's herpangina and its application | |
| KR20220156604A (en) | Application of Traditional Chinese Medicine Compositions in Preparation of Drugs for Treatment or Prevention of Coronavirus Infection | |
| WO2010040254A1 (en) | The use of flavones from radix scutellariae in manufacture of medicaments for treating enterovirus infection | |
| US20030054047A1 (en) | Pharmaceutical composition for the treatment of viral infection | |
| CN102274234B (en) | Application of ganoderic acid Y to preparation of medicament for treating or preventing enterovirus 71 infection | |
| CN106038535B (en) | Application of the aesculetin in the drug of preparation prevention and treatment II type virus infection of dengue fever | |
| JP2006219460A (en) | Anti-herpesvirus composition and method for producing fermented terminalia catappa extract having anti-herpesvirus action | |
| CN105902696A (en) | Application of Viola yedoensis in preparation of drug for preventing and treating infection of dengue II viruses | |
| CN101695511A (en) | Pomegranate rind extract and production method and application thereof | |
| CN106309470A (en) | Application of sargassum fusiforme polysaccharide | |
| CN101152202B (en) | Pharmaceutical composition for treating apparatus respiratorius disease and method for preparing the same | |
| CN102697800B (en) | Herba stellariae mediae polysaccharide composition and the application in preparation antiviral drugs thereof | |
| CN111743935A (en) | Traditional Chinese medicine composition for preventing and treating dengue fever virus and preparation method thereof | |
| CN101084991B (en) | Tibetan medicine tangut dragonhead extraction and its application in preparing antivirus medicine | |
| CN107823215A (en) | Application of the scutelloside in the medicine for preparing preventing and treating zika virus infection | |
| CN103070876B (en) | The compositions that the anti-encephalitis b virus of one class infects and application thereof | |
| CN110974867B (en) | Application of cassia twig aqueous extract in preparation of medicine for preventing and treating Zika virus infection | |
| CN102716177B (en) | Application of fresh euphorbia helioscopia juice in preparation of medicine for treating herpes simplex virus | |
| CN105582007A (en) | Novel application of osthole in preparation of echinococcosis treating drug | |
| CN113230253B (en) | Antiviral composition and application thereof in preparation of medicine for preventing and/or treating herpes virus | |
| CN108926583A (en) | The purposes of Zhejiang wintersweet anti-microbial infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |